The global anti-fungal drugs market size is likely to reach USD 13.17 billion by 2027 on account of the increasing prevalence of skin infections worldwide. Mycosis or fungal infection is a skin disease caused by a group of spore-producing organisms living and feeding on the human skin. When untreated, they lead to skin issues such as rashes, athlete’s foot, yeast infection, ringworm, nail fungus, bumps, and others.
Click here to get the short-term and long-term impact of COVID-19 on this Market.
Please visit: https://www.fortunebusinessinsights.com/industry-reports/antifungal-drugs-market-101188
Detailed Table of Content:
- Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
- Executive Summary
- Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
- Key Insights
4.1. Key Industry Developments (Mergers, Acquisitions, and Partnerships, etc.)
4.2. Prevalence of Fungal Infections
4.3. Pipeline Analysis
4.4. New Product Launches
- Global Anti-Fungal Drugs Market Analysis, Insights and Forecast, 2016-2027
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Drug Type
5.2.1. Azoles
5.2.2. Echinocandins
5.2.3. Polyenes
5.2.4. Allylamines
5.3. Market Analysis, Insights and Forecast – By Indication
5.3.1. Dermatophytosis
5.3.2. Candidiasis
5.3.3. Aspergillosis
5.3.4. Others
5.4. Market Analysis, Insights and Forecast – By Route of Administration
5.4.1. Oral
5.4.2. Topical
5.4.3. Parenteral
5.5. Market Analysis, Insights and Forecast – By Distribution Channel
5.5.1. Hospitals Pharmacies
5.5.2. Retail Pharmacies & Drug Stores
5.5.3. Online Pharmacies
5.6. Market Analysis, Insights and Forecast – By Region
5.6.1. North America
5.6.2. Europe
5.6.3. Asia pacific
5.6.4. Latin America
5.6.5. Middle East & Africa
- North America Anti-Fungal Drugs Market Analysis, Insights and Forecast, 2016-2027
6.1. Key Findings / Summary
6.2. Market Analysis – By Drug Type
6.2.1. Azoles
6.2.2. Echinocandins
6.2.3. Polyenes
6.2.4. Allylamines
6.3. Market Analysis – By Indication
6.3.1. Dermatophytosis
6.3.2. Candidiasis
6.3.3. Aspergillosis
6.3.4. Others
6.4. Market Analysis – By Route of Administration
6.4.1. Oral
6.4.2. Topical
6.4.3. Parenteral
6.5. Market Analysis – By Distribution Channel
6.5.1. Hospitals Pharmacies
6.5.2. Retail Pharmacies & Drug Stores
6.5.3. Online Pharmacies
6.6. Market Analysis – By Country
6.6.1. U.S.
6.6.2. Canada
- Europe Anti-Fungal Drugs Market Analysis, Insights and Forecast, 2016-2027
7.1. Key Findings / Summary
7.2. Market Analysis – By Drug Type
7.2.1. Azoles
7.2.2. Echinocandins
7.2.3. Polyenes
7.2.4. Allylamines
7.3. Market Analysis – By Indication
7.3.1. Dermatophytosis
7.3.2. Candidiasis
7.3.3. Aspergillosis
7.3.4. Others
7.4. Market Analysis – By Route of Administration
7.4.1. Oral
7.4.2. Topical
7.4.3. Parenteral
7.5. Market Analysis – By Distribution Channel
7.5.1. Hospitals Pharmacies
7.5.2. Retail Pharmacies & Drug Stores
7.5.3. Online Pharmacies
7.6. Market Analysis – By Country/ sub-region
7.6.1. U.K.
7.6.2. Germany
7.6.3. France
7.6.4. Spain
7.6.5. Italy
7.6.6. Scandinavia
7.6.7. Rest of Europe
- Asia pacific Anti-Fungal Drugs Market Analysis, Insights and Forecast, 2016-2027
8.1. Key Findings / Summary
8.2. Market Analysis – By Drug Type
8.2.1. Azoles
8.2.2. Echinocandins
8.2.3. Polyenes
8.2.4. Allylamines
8.3. Market Analysis – By Indication
8.3.1. Dermatophytosis
8.3.2. Candidiasis
8.3.3. Aspergillosis
8.3.4. Others
8.4. Market Analysis – By Route of Administration
8.4.1. Oral
8.4.2. Topical
8.4.3. Parenteral
8.5. Market Analysis – By Distribution Channel
8.5.1. Hospitals Pharmacies
8.5.2. Retail Pharmacies & Drug Stores
8.5.3. Online Pharmacies
8.6. Market Analysis – By Country/ sub-region
8.6.1. Japan
8.6.2. China
8.6.3. India
8.6.4. Australia
8.6.5. Southeast Asia
8.6.6. Rest of Asia Pacific
- Latin America Anti-Fungal Drugs Market Analysis, Insights and Forecast, 2016-2027
9.1. Key Findings / Summary
9.2. Market Analysis – By Drug Type
9.2.1. Azoles
9.2.2. Echinocandins
9.2.3. Polyenes
9.2.4. Allylamines
9.3. Market Analysis – By Indication
9.3.1. Dermatophytosis
9.3.2. Candidiasis
9.3.3. Aspergillosis
9.3.4. Others
9.4. Market Analysis – By Route of Administration
9.4.1. Oral
9.4.2. Topical
9.4.3. Parenteral
9.5. Market Analysis – By Distribution Channel
9.5.1. Hospitals Pharmacies
9.5.2. Retail Pharmacies & Drug Stores
9.5.3. Online Pharmacies
9.6. Market Analysis – By Country/ sub-region
9.6.1. Brazil
9.6.2. Mexico
9.6.3. Rest of Latin America
- Middle East & Africa Anti-Fungal Drugs Market Analysis, Insights and Forecast, 2016-2027
10.1.Key Findings / Summary
10.2.Market Analysis – By Drug Type
10.2.1. Azoles
10.2.2. Echinocandins
10.2.3. Polyenes
10.2.4. Allylamines
10.3.Market Analysis – By Indication
10.3.1. Dermatophytosis
10.3.2. Candidiasis
10.3.3. Aspergillosis
10.3.4. Others
10.4.Market Analysis – By Route of Administration
10.4.1. Oral
10.4.2. Topical
10.4.3. Parenteral
10.5.Market Analysis – By Distribution Channel
10.5.1. Hospitals Pharmacies
10.5.2. Retail Pharmacies & Drug Stores
10.5.3. Online Pharmacies
10.6.Market Analysis – By Country/ sub-region
10.6.1. GCC Countries
10.6.2. South Africa
10.6.3. Rest of Middle East & Africa
Continued...
